How Commercial Insights Can be Used to Maximize an Early Exit
About this webinar
Out-licensing or selling an asset prior to the initiation of pivotal Phase III studies or an NDA submission is always challenging. However, the likelihood of effecting an attractive exit can be significantly enhanced through proactive, strategic planning and the use of commercial insights. To realize an early exit before Phase III or NDA submission, it is critical that sponsors understand the out-licensing environment and develop a cohesive commercial strategy that articulates how the success of the product can be maximized.
This webinar will provide an overview of the commercial insights that should be gathered in the early phases of development and will provide guidance on best practices to use these insights to:
- Focus and drive the development process,
- Identify the right type of commercial partners, and
- Enhance the ability to negotiate better terms for an exit or out-licensing deal.
Who should attend
- R&D Leadership
- Commercial Leadership
- Commercial Affairs
- Business Development
- Regulatory Affairs
- Market Access
- Project Management
What you will learn
In this webinar, participants will learn:
- Which key commercial and strategic insights should be gathered in the early phases of product development
- Best practices for identifying and engaging with commercialization partners
Featured Speakers
Robb Lawrence
Robb Lawrence joined Camargo in 2020 as Senior Vice President of Commercial Strategy, taking responsibility for Camargo’s expanding suite of commercial strategy solutions. Prior to this, he spent 10 years as a health care entrepreneur, building companies focused on bringing innovative products to the US market. He was the founding CEO of two virtual specialty pharmaceutical companies, both established to advance partnerships negotiated with large global pharmaceutical companies.
Previously, Mr. Lawrence established a successful global consulting practice focused on strategic product development and go-to-market strategies for novel medicines. He began his career in pharmaceuticals at Merck & Company, where he held numerous positions in marketing and commercial operations and played a key role in the launch of Merck’s Diabetes Franchise.
Mr. Lawrence earned an MBA with a focus in Health Sector Management from Duke University’s Fuqua School of Business and a BA in Literature and History from Wake Forest University.
Partner for this event
Camargo
Camargo is a strategic drug development, regulatory, and commercial partner for emerging biopharma companies focused in rare and complex therapeutic areas. We have expertise in rare disease, oncology, pediatrics, the 505(b)(2) regulatory pathway, and more specialty areas. Our integrated Strategy, Regulatory, Nonclinical, and Clinical solutions help clients accelerate development from concept to commercialization.
For nearly 20 years, we have helped clients successfully position high-science, creatively bold strategies to regulators and accelerate development with confidence.
Headquartered in the United States, we have offices in Cincinnati, Ohio; Durham, North Carolina; and Montreal, Québec. We are proud to partner with clients in more than 35 countries around the world.